foxo4-dri human trial peptide senolytic Development of a novel senolytic by precise disruption of FOXO4 Senolytics: from pharmacological inhibitors to
Description
By selectively targeting fat cells without affecting muscle tissue, it shifts the weight loss equation toward preferential fat loss
It was first isolated and characterised by Professor Predrag Sikiric and his research group at the University of Zagreb in the early 1990s, with the foundational paper published in the Journal of Physiology (Paris) in 1993
*Frontiers in Pharmacology*, 12, 634151
For more information, contact us or book an appointment
Regulatory rules are in flux, and product quality is all over the map
BPC-157 has become increasingly popular for a variety of health issues
